Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapsone topical - Almirall S.A.

Next Previous
X
Search
Drug Profile

Dapsone topical - Almirall S.A.

Alternative Names: 5% Topical dapsone gel - Novelion Therapeutics; 7.5% Topical dapsone gel - Allergan; Aczone; Atrisone

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT
  • Developer Almirall S.A.; Novelion Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antibacterials; Antileprotics; Antimalarials; Antivirals; Small molecules; Sulfones
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 11 Sep 2019 Launched for Acne vulgaris (In children) in USA (Topical,Gel)
  • 10 Sep 2019 Registered for Acne vulgaris (In children) in USA (Topical, Gel)
  • 03 Aug 2018 Almirall S.A. acquires dapsone topical from Allergan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top